AI Summary The DCP (PIVKA-II) test is a blood tumor marker that helps doctors watch for hepatocellular carcinoma (HCC), the most common primary liver cancer. Doctors read it with a liver ultrasound and other markers, such as AFP and AFP-L3, never alone. People with cirrhosis or a past HCC may be tested. A high result raises suspicion but does not diagnose cancer; doctors confirm HCC with contrast CT or MRI, or a biopsy. Your doctor decides which tests you need and how often.
Source: www.liverdirectory.com
Medically Reviewed.
The DCP test, also called the PIVKA-II test, measures a tumor marker in your blood. A tumor marker is a substance that can change when a cancer is present. DCP is linked to hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
Doctors read a DCP result together with a liver ultrasound, not on its own. A high result raises suspicion but does not diagnose cancer. This page explains who may be tested, how DCP compares with AFP, what a result can mean, and what happens next.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
Tumor Marker Basics
The DCP test measures des-gamma-carboxy prothrombin (DCP) in a sample of your blood. Doctors also call it PIVKA-II. It is a routine blood draw.
DCP is one of three tumor markers doctors use for liver cancer. The other two are alpha-fetoprotein (AFP) and AFP-L3. Early liver cancer often causes no symptoms, so doctors check on a schedule when liver disease puts a person at high risk of hepatocellular carcinoma (HCC).
DCP is a clue, not a verdict. The American Association for the Study of Liver Diseases (AASLD) advises against using blood biomarkers to diagnose HCC, because they are not accurate enough. Your care team reads the result together with your imaging, your liver disease, and your symptoms.
HCC Surveillance Eligibility
Tumor marker testing is for people whose liver disease raises their risk of HCC. Your doctor decides which tests you need and how often.
AASLD advises HCC surveillance for adults with Child-Turcotte-Pugh A or B cirrhosis, from any cause. About 1% to 8% of people with cirrhosis develop HCC each year, depending on the cause of their liver disease. The standard routine is an ultrasound with an AFP test every 6 months. Your doctor may add other markers.
APASL guidance treats a previous HCC as very high risk. These patients are seen every 4 months for an abdominal ultrasound plus tumor markers such as AFP, AFP-L3, and/or DCP.
EASL guidance says people with cirrhosis need lifelong HCC surveillance, even after a sustained virologic response (SVR), which means the hepatitis C virus is no longer detected. Learn more about [viral hepatitis treatments](/liver-therapies/viral-hepatitis-treatments).
AASLD recommends against surveillance in people with Child-Turcotte-Pugh C cirrhosis who cannot have a liver transplant. It also advises against it when another serious illness limits life expectancy to less than 1 to 2 years and cannot be fixed by transplant or other directed therapy.
Liver Cancer Screening Options
No single marker or scan does everything. Doctors combine them.
| Check | What It Is | Role in Current Guidance |
|---|---|---|
| Liver ultrasound | An imaging scan of the liver | The standard first check, usually every 6 months in people with cirrhosis |
| AFP | Blood tumor marker | Paired with ultrasound; it finds more early-stage HCC but lowers specificity, so some high results are false alarms. EASL says a level above 15 ng/mL should raise suspicion |
| AFP-L3 | Blood tumor marker | Named with AFP and DCP for 4-month checks after a previous HCC |
| DCP (PIVKA-II) | Blood tumor marker | Named with AFP and AFP-L3 for 4-month checks after a previous HCC. EASL says markers other than AFP lack enough long-term data to replace ultrasound |
| Contrast CT or MRI | Detailed imaging scans | Used to diagnose HCC in high-risk patients, using LI-RADS criteria |
Head-to-head accuracy figures for DCP are not available, so this table does not rank the tests.
Understanding Your Test Result
A high result raises suspicion, but it does not prove cancer. AASLD advises against using biomarkers to diagnose HCC. Your doctor will usually order more imaging. For nodules that look unclear on imaging, AASLD says raised tumor markers such as AFP can prompt closer imaging or a biopsy.
A normal result is reassuring, but markers are not accurate enough to stand alone. Keep your scheduled ultrasounds either way.
This page does not give DCP cutoffs. Labs report results in their own units and ranges, so read your number against the range printed on your report, and ask your care team what it means for you.
After an Abnormal Marker
A high result is a reason for a closer look, not a diagnosis. These steps are typical.
Your doctor compares the result with your last ultrasound and earlier markers.
You may have a contrast-enhanced CT or MRI. HCC shows up as arterial phase hyperenhancement and washout, graded by LI-RADS. EASL prefers extracellular contrast MRI for first diagnosis.
If imaging stays unclear, you may have a biopsy. EASL says biopsy is needed in people who are not at high risk, such as MASLD without cirrhosis. Read about [liver biopsy](/liver-tests/invasive-testing/liver-biopsy).
If HCC is confirmed, your team discusses [liver cancer therapies](/liver-therapies/liver-cancer-therapies).
Appointment Preparation Tips
Bring these questions to your next appointment with your liver specialist.
A balanced, liver-friendly diet supports your liver, helps manage weight and blood sugar, and lowers the risk of other health problems during long-term follow-up.
Explore Liver DietThe Amsety Bar is a liver-friendly snack or meal replacement that can make it easier to eat well on busy days.
Shop Amsety Bars
Common Questions
Yes. DCP (des-gamma-carboxy prothrombin) and PIVKA-II are two names for the same tumor marker. Guidelines and lab reports may use either name, so you might see one on your lab report and the other in an article or guideline. A tumor marker is a substance in your blood that can change when a cancer is present. DCP is one of three tumor markers doctors use for hepatocellular carcinoma (HCC). The other two are AFP and AFP-L3.
No. A high level raises suspicion but does not diagnose cancer. AASLD advises against using blood biomarkers to diagnose HCC, because they are not accurate enough. After a high result, your doctor will usually order more imaging. Doctors confirm HCC with contrast-enhanced CT or MRI, or with a biopsy when imaging is unclear. Your care team reads the result together with your imaging, your liver disease, and your symptoms.
No. Tumor markers are not accurate enough to stand alone, so a normal result is reassuring but does not rule out cancer. Early liver cancer often causes no symptoms. That is why doctors check on a schedule when liver disease puts a person at high risk. Keep your scheduled ultrasounds even when a marker result is normal.
It depends on your risk, and your doctor sets your schedule. After a previous HCC, APASL guidance pairs an abdominal ultrasound with AFP, AFP-L3, and/or DCP every 4 months. For people with cirrhosis, the routine check is an ultrasound and an AFP test every 6 months, and your doctor may add other markers. Ask which tests you need and how often.
Not clearly. AFP is the marker paired with ultrasound in routine guidance. It finds more early-stage HCC but lowers specificity, so some high results are false alarms. EASL says serum markers other than AFP show promise but lack enough long-term data to replace ultrasound for routine screening. Head-to-head accuracy figures for DCP are not available. Ask your doctor which markers fit your case.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
